Biosimilars have been available in Europe since 2006. Novartis is currently waiting on FDA decision on its first in the US biosimilar of Neupogen.

Remicade (Johnson&Johnson), Epogen (Amgen) and Rituxan (Roche) will face generic competition in the near future. FirstWord Pharma cited Bloomberg estimate of 250 bln USD in savings to US budget by 2014 due to biosmilars use.